Background: Patient-reported outcomes are important for clinical research and care, yet administering and scoring the questionnaires requires considerable effort and time. The Patient Reported Outcomes Measurement Information System (PROMIS) could considerably reduce administrative obstacles and lessen survey burden for participants. Objective: Assess the feasibility and validity of PROMIS, compared to commonly-used legacy measures for multiple sclerosis (MS). Methods: In this cross-sectional survey, 133 participants with confirmed MS completed legacy surveys and PROMIS Computerized Adaptive Tests (CATs) for depression, anxiety, pain, fatigue and physical function. We conducted a multitrait, multi-method analysis and verified results with confirmatory factor analysis. Results: The correlations between PROMIS and the corresponding legacy measures were large (0.67 to 0.87). The multi-trait, multi-method criteria were generally well met, providing good evidence of the validity of PROMIS measures. PROMIS surveys asked fewer questions and required substantially less time to complete than the legacy scales. Conclusions: Our results provide evidence of the construct validity of PROMIS for use with MS patients. Several aspects of the PROMIS CATs made them an important resource, including: (a) less time was required to complete them; (b) missing data was reduced; and (c) the automatic scoring referenced the general population. Our findings support the use of PROMIS in MS research and may have broader implications for clinical care, as well.
Introduction
Patient-reported outcomes (PROs) quantify a person's experience with their health and the effect of treatment on how they feel or function. As the patient is the only reliable source of this information, PROs are important outcomes in both clinical care and research settings. There are, however, substantial obstacles to collecting PROs. Administering questionnaires, dealing with missing data, scoring surveys and effectively storing data require considerable time from providers and researchers. Longer surveys can lead to respondent fatigue and place additional burden on patients with disease, potentially resulting in mistakes and lower completion rates. 1 The Patient Reported Outcomes Measurement Information System (PROMIS) is a free, NIH-funded, online repository of PROs with the novel capability of administering computerized adaptive tests (CATs). 2 These CATs reduce survey length by selecting the most informative question, based on the participant's prior response. In reducing the number of questions asked, PROMIS may improve the survey experience for participants, minimize the risk of missing data and substantially reduce administration burden.
Multiple sclerosis (MS) research has long used legacy scales to collect PROs. In order to validate the PROMIS CAT measures for future use in MS research, we conducted a cross-sectional survey (n = 133) in which respondents completed both PROMIS and related legacy measures. Our objective was to explore the feasibility and validity of PROMIS compared to legacy measures for depression, anxiety, fatigue, pain and physical function in MS. Results may not only be applicable to MS research, but have broader implications for clinical care, as well.
Materials and methods
The current analysis was part of a study whose primary aim was to assess the relationship between self-reported mindfulness and perceived stress in MS. The evaluation of PROMIS and legacy scales was established a priori as an exploratory aim. Sample size (n = 150) was calculated in order to find correlations between primary outcomes of at least .30 with 80% power, an alpha = .05 and a 5% loss of data.
Design, setting and study participants
Recruitment began after approval from the Oregon Health and Science University (OHSU) Institutional Review Board (IRB). Participants were scheduled for one study visit, to complete both the legacy and PROMIS questionnaires. We recruited a convenience sample of men and women during their outpatient visits to the MS Center at OHSU. The study was also advertised with the National MS Society's local chapter and through MS community events. Inclusion criteria comprised any type of MS, ability to read and write in English, and age from 18 to 90 years old. Exclusion criteria included a relapse or exacerbation within the previous 90 days. MS diagnosis was confirmed by chart review, according to 2010 McDonald criteria. 3 Between December 2011 and February 2013, 150 people with MS gave written informed consent and completed the study.
Outcome measures
All legacy questionnaires are validated surveys used in clinical trials of MS patients. All these outcome measures ask participants to rate their experience on a Likert-type scale. Legacy measures were administered by pen and paper; PROMIS measures were administered using a laptop computer. The measures used were:
1. Beck Depression Inventory I (BDI): BDI is a 21-item survey. Total BDI scores range from 0-63; higher scores indicate higher levels of depression. 4 2. State-Trait Anxiety Inventory (STAI): STAI consists of two 20-item subscales, one that assesses anxiety in the present moment (the state) and one that assesses dispositional anxiety (the trait). 5 For this analysis, only trait anxiety was used. The STAI trait subscale score has a range from 20-80, where higher scores reflect more anxiety. 3. Modified Fatigue Impact Scale (MFIS): MFIS is a 21-item survey derived from the Fatigue Impact Scale. 6, 7 The total MFIS score ranges from 0-84; higher scores reflect more fatigue.
Medical Outcomes Study Pain Effects Scale (PES):
A 6-item scale assessing the effects of pain on behavior and mood over the past 4 weeks. 7, 8 Scores range from 6-30; higher scores indicate more pain.
Physical Function subscale of the Short Form-36
(SF-36): The SF-36 is a generic measure of healthrelated quality of life, comprised of eight subscales. 9, 10 Subscales are scored on a T-scale metric with the mean score of a general US population equal to 50 and a standard deviation (SD) of 10.
Higher scores indicate better physical function. 6. PROMIS CAT 1.0 inventories: These include depression, anxiety, fatigue, pain interference and physical function. [11] [12] [13] The surveys are administered and scored via a web-based application hosted by the Assessment Center SM . The CATs were configured to administer enough items to achieve a standard error (SE) of < 0.30 after a minimum of 4 questions were asked. Each CAT stopped after a maximum of 12 questions, regardless of whether the SE criterion was met. Scores were reported on a T-score metric, normalized so that population mean equals 50 and SD is 10.
Statistical analysis
We evaluated the construct validity of PROMIS measures using a multi-trait, multi-method matrix (MTMM). 14 MTMM analysis involves correlating the scores of different traits (e.g. depression, anxiety, pain, etc.) across different methods of investigation (e.g. PROMIS versus legacy instruments). Strong correlations between two different methods measuring a single trait (e.g. PROMIS and legacy measures for depression) support convergent construct validity, whereas weaker correlations among measures of different traits are evidence of discriminant validity. The detailed MTMM criteria that must be fulfilled in order to support construct validity are described by Campbell and Fiske. 14 Preliminary analyses were performed using STATA 12. We used descriptive analyses to summarize the demographic information and the outcomes for PROMIS and legacy instruments. Cronbach's alpha was generated for all legacy surveys, as a measure of internal consistency. 15 Due to the CAT format, alpha for PROMIS measures could not be computed from study data. Alphas for PROMIS scales, applied to a more general population, are provided by the Assessment Center SM and are provided here for reference. An alpha > 0.80 is generally considered satisfactory as a measure of survey reliability. 16 The following were used for the strength of correlation coefficients: r of 0.0-0.29 was a small, 0.30-0.49 a moderate, 0.50-0.74 a good and r > 0.75 a strong relationship. 17 A comparison of correlation coefficients was considered successful if the validity coefficient was significantly larger than the comparison coefficient (p < 0.05). 18 Calculations of significance were programmed with R software, v.2.15.1. Each comparison of correlations was tested using the maximum amount of data available (n = 133). Due to an oversight in administering the legacy surveys, fatigue data was not available for 19 of these 133 participants; thus, comparisons in which at least one correlation involved legacy fatigue methods were made with the data for 114 participants.
To substantiate the MTMM analysis, confirmatory factor analysis (CFA) was conducted using the R's sem package to test for underlying trait and method effects (www.r-project.org). The principal model loaded the PROMIS and legacy measures onto the corresponding latent trait factors of depression, anxiety, fatigue, pain and physical function. For CFA, the 19 missing legacy fatigue measures were imputed as the mean fatigue scores of the other 114 participants. CFA was then conducted on data for all 133 participants who completed the PROMIS scales.
Results

Participant characteristics
We approached 214 people with MS to participate in this study (Figure 1 ). Missing and excluded data resulted in sample sizes for individual scales that varied between 120 and 146 individuals. Their demographic data is displayed in Table 1 .
Descriptive statistics for legacy and PROMIS questionnaires are presented in Table 2 . We administered the surveys in the same order for each visit. Because PROMIS was an exploratory aim, we administered these questionnaires at the end of the visit. Several participants experienced survey fatigue and were unable to complete the entire study (n = 13); this left 133 participants whom completed both PROMIS and legacy surveys ( Table 1) . Noncompleters reported greater levels of disability: 69% reported needing at least some kind of regular walking support, compared to 26% of those that completed PROMIS. Additionally, there were more participants with primary or secondary progressive MS in the non-completer group (62% versus 25%, Table 1 ). Legacy scores with available normative data were converted to a T score metric, to enhance comparability with PROMIS data (Table 3) .
Feasibility
Legacy questionnaires were completed by pen and paper; PROMIS questionnaires were completed online. Six participants required modifications to study administration, due to poor vision or hand tremors: Survey questions were read aloud to one participant, whom provided verbal responses that were recorded by study staff, and five other participants read each question themselves and then verbally spoke their answers to the study staff. There was no difference between the modifications made for the legacy and PROMIS scales.
PROMIS asked fewer questions, compared to corresponding legacy instruments, with the exception of the pain surveys ( Table 2 ). The average time to complete all five PROMIS surveys was 4.08 minutes. Participants were not timed during the legacy surveys, although the estimated time to complete all five legacy surveys was 15.6 minutes (78 questions, estimated at 5 questions/min). 1
Multi-trait, multi-method analysis
The MTMM matrix is provided in Table 4 . Reliability coefficients (in italics) were consistently strong (ranging from .91 to .97) and, as expected, were the largest coefficients in the matrix. Validity coefficients (in bold) are good to strong (ranging from .67 to .87). Validity coefficients should be higher than correlations in their row and column within the PROMIS versus Legacy quadrant of the matrix. Fatigue, pain and physical function met this criterion 100% of the time, depression 87.5% of the time and anxiety 75% of the time. Validity coefficients should be higher than all offdiagonal coefficients in the PROMIS versus PROMIS and the Legacy versus Legacy quadrants. Pain and physical function met this criterion 100% of the time; while fatigue met it 95%, depression 85% and anxiety 60% of the time. Significant interrelationships among traits were present within the matrix. This was acceptable, as the pattern of trait interrelationship appeared to be consistent between methods. 14 
Confirmatory factor analysis
To verify our results from the MTMM analysis, a confirmatory factor analysis determined whether covariance of the 10 measured scales could be explained by covariance of the five latent factors of depression, anxiety, fatigue, pain and physical function. In the initial model, we loaded each legacy and PROMIS measure onto one of five corresponding latent trait factors (e.g. the PROMIS Depression and Legacy Depression measures were allowed to load onto a single latent Depression factor.) This returned a chi-squared statistic of χ 2 (25) = 43.22; p = 0.013; a goodness-of-fit index of 0.940 and RMSEA index of 0.074, indicating there was a good fit to the observed MTMM matrix. All loadings onto trait factors were > 0.80 and significant (p < 10 -25 ), indicating the strong convergent validity of the PROMIS and legacy measures. The factor loadings and correlations are available in the supplementary materials. Additional CFA modeling using two method factors and no traits yielded a method-method correlation > 0.95. This suggested that any variation seen in scores between PROMIS and legacy scales was not due to systematic differences between the two methods of administration.
PROMIS outcomes by MS subtype
Mean PROMIS scores categorized by MS subtype are presented in Figure 2 . As expected, participants with progressive disease report lower levels of physical function than Table 3 . Comparison of the legacy and PROMIS scales. All scores were converted to a T scale referenced to the general population, with a mean of 50 and SD of 10; however, the legacy fatigue and pain scales used in this study are specifically designed for MS, therefore they do not have normative data for the general US population that would allow for conversion to a T metric. those with relapsing-remitting MS. Correspondingly, Figure 3 displays the physical outcomes (fatigue, pain and physical function), categorized by self-reported level of disability. Physical function scores progressively decline across all categories, from 'no disability' to 'unable to walk'. Fatigue and pain increase across the first four categories, from 'no disability' to 'some support needed', and then decline over the last two categories. Because there were few progressive participants in this study, these data should be viewed as descriptive and future studies should confirm our results with larger numbers of progressive participants.
Discussion
Patient-reported assessments of depression, anxiety, fatigue, pain and physical function are essential in the care of people with MS and are important outcomes in clinical trials. MS research has long used legacy instruments to collect this information. Before adopting the novel PROMIS methodology, the relationship of PROMIS CAT measures to these traditional surveys needs to be understood. We found strong correlations between corresponding scales (0.67-0.87). In addition, the PROMIS measures asked fewer questions, required substantially less time to complete and had no missing data, compared to legacy scales. One of the aims of PROMIS is to improve precision while reducing survey burden for participants. In general, longer surveys result in lower completion rates; this is particularly true for those with more advanced disease, who may have difficulty sustaining attention, holding a pen or focusing their vision for long periods of time. Indeed, for these reasons, we lost 13 of 146 participants over the course of our survey. Our non-completers reported higher levels of disability than the completers; however, it was our experience that people with advanced disability had no more difficulty completing PROMIS, as compared to the legacy scales. On the contrary, because it requires less time and fewer questions to complete, we believe that using PROMIS increases the likelihood that self-reported data is collected from people across the disability spectrum. In total, completion of the PROMIS scales required an average of 24.3 items, compared to the 78 items in the corresponding legacy scales. It is unsurprising that PROMIS requires fewer items, given that each CAT was programmed to ask no more than 12 questions. Here, the interesting result is how many fewer questions were required by PROMIS surveys. Even with a stopping rule set at 12 questions, the average number of questions asked per PROMIS survey was only 4.86. Our data suggested that the PROMIS and legacy scales provided similar results, even though the PROMIS surveys tended to be substantially shorter.
Reducing the number of questions asked while preserving reliability will improve the survey experience for participants and minimize the risk of missing data. The average completion time for the five PROMIS scales was 4.08 minutes. As a rule of thumb, a typical response time for Likerttype questionnaires is three to five questions per minute. 1 For the five legacy scales, with a total of 78 items, an estimated completion time would be 15-26 minutes. This rule of thumb applies to a general population, so response times could be substantially longer for those with cognitive or physical limitations. Thus, reducing the survey length has great implications for clinical research in neurology.
Additional benefits of using PROMIS in this study included no missing data. Participants were automatically reminded to answer any question unintentionally left blank and if the respondent deliberately skipped a question, the CAT will substitute in alternative, equivalent questions. Although the study staff reviewed each legacy scale upon completion, it was impossible to avoid missing data for these pen-and-paper surveys. In addition, both raw and T scores for CATs were immediately available from Assessment Center SM , substantially reducing the time devoted to scoring and data entry. Under real-world conditions, this will inevitably lead to more reliable outcomes. Because these surveys are free, quick to administer, and automatically scored while the patient is potentially still in the office, the PROMIS CATs may also work well in a clinical care setting. One academic center reports using PROMIS successfully, without disruption to the flow of the clinic, although more publications are needed in this area. 20 While there were several advantages to using PROMIS, there are also limitations that should be considered. CATs require some kind of computer interface with real-time internet access, to upload the patient's responses to the Assessment Center SM database. This may pose a logistical problem for some trials or clinical assessments. PROMIS surveys can be administered as static questionnaires and delivered by the pen-and-paper format, but static forms must be hand graded, even when administered electronically. Finally, a significant challenge for utilizing PROMIS assessments in clinical care remains how to seamlessly integrate the data into electronic health records (EHR) without a substantial increase in clinical staff workload.
Correlations between corresponding PROMIS and legacy measures were strong, but not perfect. To the extent that our common understanding of health is often guided by legacy scales, the PROMIS measures may therefore convey somewhat less information; however, the MTMM analysis can only assess the amount of overlap between PROMIS and legacy scores, and not how well either method measures the true underlying characteristic of interest. It is unclear if any information was lost with PROMIS, and it is possible that PROMIS measures were actually more informative about the real state of the respondent. For example, others demonstrate that the PROMIS physical function questions better differentiate among the people with higher physical function than the SF-36 subscale. 21 Indeed, we found a discrepancy between the means of the PROMIS and legacy physical function scales ( Table 3 ) that likely resulted from the PROMIS scale's lack of an artificial upper bound on the rating of physical function. In this case, a less than perfect correlation between PROMIS and legacy physical function may indicate that PROMIS provided more accurate information than the legacy measure. Future validity studies may aim to assess differences in information capture between the PROMIS and legacy scales.
Despite potential limitations, we found PROMIS feasible for use in clinical research with good evidence of construct validity. To establish its validity for longitudinal studies, it is necessary to determine minimally-important differences, test-retest reliability and responsiveness to change in MS. Yost et al. suggest that minimally important differences for cancer participants (using the static PROMIS scales depression, anxiety, fatigue, pain interference and physical functioning) range between 3 and 6 points. 22 Broderick et al. show that 7-day test-retest reliability is strong (≥ .80) for 98 osteoarthritis participants completing the PROMIS scales for pain intensity, pain interference, physical functioning and fatigue. Finally, Fries et al. provide evidence of responsiveness to change for static PROMIS physical function forms over a 12-month period, for people with rheumatoid arthritis. 23 Based on these findings, PROMIS has good potential for use in longitudinal studies, although MS-specific psychometrics should continue to be established. 25 Few studies evaluate the use of PROMIS in MS 24, 26, 27 and to our knowledge, this is the first study to examine the association between the legacy and PROMIS CAT measures of depression, anxiety, fatigue, pain and physical function in MS. Our study had limitations, as most participants came from a single center, so this convenience sampling may have led to an under-or over-representation of certain factors within our sample. Indeed, only 10.5% of our participants (14/133) reported having moderate to severe depression (> 21 on the BDI). The point prevalence for depression in MS clinical samples is often estimated closer to 30%, [28] [29] [30] potentially limiting the generalizability of our results.
We also did not time participants as they completed the legacy scales and instead, used a general rule of thumb to compare completion times. Nevertheless, our estimates were conservative for a general population and may have underestimated the true impact that PROMIS surveys could have in patients with neurological conditions. Finally, this was a cross-sectional study. Future longitudinal studies that collect PROMIS outcomes will help to identify minimally important differences, responsiveness to change and testretest reliability in the MS population.
Despite the potential limitations, we found PROMIS feasible for use in MS research, with good evidence of construct validity. Several benefits of PROMIS CATs outweighed the use of legacy scales, including: Figure 3 . Mean PROMIS T scores for fatigue, pain and physical function by self-reported disability in a cross-sectional cohort (n = 133). T scores were anchored to a general population mean of 50, with a SD of 10. Higher scores indicate more of the trait being measured (e.g. fatigue scores above 50 indicate more fatigue than the average general population, physical function scores above 50 indicate more/better physical function than the average general population). PROMIS results may not only be applicable to MS, but may also have broader implications for a range of neurological conditions in which survey burden is a major concern. In addition to being a research tool, clinicians also have easy access to PROMIS: They may find benefit in using these surveys in a clinical setting.
